Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
FDA approval of a generic nintedanib esylate formulation; establishes bioequivalence and manufacturing compliance but does not report clinical efficacy or comparative trial data.